Lonza agreed to divest its capsules and health‑ingredients business to a UK investment firm for $2.2 billion upfront, executing a strategic separation of its consumer health manufacturing assets. The sale follows a long‑running plan to streamline Lonza’s focus on biomanufacturing and high‑value pharma services. Management said proceeds will support core biologics and advanced therapy investments while enabling the buyer to scale capsule and ingredient operations independently.